Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have attracted interest as potential treatments for alcohol use disorder (AUD) after patients receiving these agents for obesity or type 2 diabetes reported a reduced desire to drink. This editorial examines whether current evidence supports their classification as broadly applicable addiction treatments or as phenotype-enriched therapies. Randomized trials evaluating exenatide and semaglutide suggest a clinically relevant but endpoint-selective signal. Reductions have been most consistent in heavy-drinking days, drinks per drinking day, naturalistic craving, alcohol-related consequences, and the World Health Organization (WHO) risk drinking level, whereas effects on total alcohol consumption, drinking frequency, and laboratory cue-elicited craving have been less consistent. Durable abstinence, sustained benefit after treatment discontinuation, prevention of alcohol-related hospitalization in randomized trials, and mortality benefit remain unestablished. Obesity may enrich treatment response and provide an independent metabolic indication, but current evidence neither identifies it as a necessary response biomarker nor establishes that alcohol reduction is mediated by weight loss. We therefore propose a three-axis clinical selection framework based on alcohol phenotype, metabolic phenotype, and treatment safety and feasibility. The strongest current rationale may be for patients with heavy episodic or loss-of-control drinking who also have obesity, type 2 diabetes, or substantial cardiometabolic risk. GLP-1 RAs should presently be regarded as candidate harm-reduction therapies that complement established AUD care, not as treatments for acute alcohol withdrawal or universal substitutes for approved pharmacotherapy. Larger comparative trials incorporating mechanistic outcomes and post-discontinuation follow-up are needed.
